drugset / Trial / NCT03145766

Immunogenicity and Safety of a Purified Vero Rabies Vaccine

NCT03145766

Phase 2 Completed 320 enrolled Sanofi Pasteur, a Sanofi Company
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This multicenter, observer-blind, controlled, randomized, Phase II study was designed to evaluate different formulations of the Purified Vero Rabies Cell vaccine VRVg.

Timeline

Start
2017-04-17
Primary completion
2018-01-08
Completion
2018-01-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Imovax® Rabies Vaccine Intramuscular
Subject VRVg 1 Unknown Intramuscular
Subject VRVg-2 Vaccine Intramuscular
Background Human Rabies Immunoglobulins (HRIG) Protein / enzyme biologic Intramuscular

Indications